MedTrace Logo

Risperidone vs. Bupropion ER Augmentation of SSRIs in Treatment-Resistant Depression

NCT00179244 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2015-06-02

No results posted yet for this study

Summary

The purpose of this study is to evaluate the comparative effectiveness of Risperdal (risperidone) or bupropion ER (extended release) combined with a SSRI medication and to test the relative safety of the combinations.

Conditions

  • Unipolar Depression

Interventions

DRUG

Rispridone (drug) and Bupropion ER (drug)

Sponsors & Collaborators

  • Janssen Pharmaceutica

    collaborator INDUSTRY

  • Vanderbilt University

    lead OTHER

Principal Investigators

  • Richard C Shelton, MD · Vanderbilt University Medical Center

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-07-31
Completion
2005-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00179244 on ClinicalTrials.gov